Search Page

1

Cite

Share

Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies.

Yang F, Paccaly AJ, Rippley RK, Davis JD, DiCioccio AT. Yang F, et al. Among authors: rippley rk. J Pharmacokinet Pharmacodyn. 2021 Aug;48(4):479-494. doi: 10.1007/s10928-021-09739-y. Epub 2021 Mar 16. J Pharmacokinet Pharmacodyn. 2021. PMID: 33728546 Free PMC article.

Cite

Share

2

Cite

Share

Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis.

Paccaly AJ, Migden MR, Papadopoulos KP, Yang F, Davis JD, Rippley RK, Lowy I, Fury MG, Stankevich E, Rischin D. Paccaly AJ, et al. Among authors: rippley rk. Adv Ther. 2021 May;38(5):2365-2378. doi: 10.1007/s12325-021-01638-5. Epub 2021 Mar 25. Adv Ther. 2021. PMID: 33768419 Free PMC article. Clinical Trial.

Cite

Share

3

Cite

Share

Metabolism and renal elimination of gaboxadol in humans: role of UDP-glucuronosyltransferases and transporters.

Chu XY, Liang Y, Cai X, Cuevas-Licea K, Rippley RK, Kassahun K, Shou M, Braun MP, Doss GA, Anari MR, Evers R. Chu XY, et al. Among authors: rippley rk. Pharm Res. 2009 Feb;26(2):459-68. doi: 10.1007/s11095-008-9799-5. Epub 2008 Dec 11. Pharm Res. 2009. PMID: 19082692

Cite

Share

4

Cite

Share

Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans.

Kochansky CJ, Rippley RK, Yan KX, Song H, Wallace MA, Dean D, Jones AN, Lasseter K, Schwartz J, Vincent SH, Franklin RB, Wagner J. Kochansky CJ, et al. Among authors: rippley rk. Drug Metab Dispos. 2006 Sep;34(9):1457-61. doi: 10.1124/dmd.106.010231. Epub 2006 Jun 13. Drug Metab Dispos. 2006. PMID: 16772365 Clinical Trial.

Cite

Share

5

Cite

Share

Human pharmacokinetics and interconversion of enantiomers of MK-0767, a dual PPARalpha/gamma agonist.

Rippley RK, Yan KX, Matthews ND, Greenberg HE, Herman GA, Wagner JA. Rippley RK, et al. J Clin Pharmacol. 2007 Mar;47(3):323-33. doi: 10.1177/0091270006297141. J Clin Pharmacol. 2007. PMID: 17322144 Clinical Trial.

Cite

Share

6

Cite

Share

Pharmacokinetic assessment of an oral enalapril suspension for use in children.

Rippley RK, Connor J, Boyle J, Bradstreet TE, Hand E, Lo MW, Murphy MG. Rippley RK, et al. Biopharm Drug Dispos. 2000 Dec;21(9):339-44. doi: 10.1002/bdd.241. Biopharm Drug Dispos. 2000. PMID: 11523062 Clinical Trial.

Cite

Share

7

Cite

Share

Quantitative determination of a novel insulin sensitizer and its para-hydroxylated metabolite in human plasma by LC-MS/MS.

Riffel KA, Polinko MA, Song H, Rippley RK, Lo MW. Riffel KA, et al. Among authors: rippley rk. J Pharm Biomed Anal. 2004 May 28;35(3):523-34. doi: 10.1016/j.jpba.2004.01.004. J Pharm Biomed Anal. 2004. PMID: 15137977

Cite

Share

8

Cite

Share

Effects of cellular pharmacology on drug distribution in tissues.

Rippley RK, Stokes CL. Rippley RK, et al. Biophys J. 1995 Sep;69(3):825-39. doi: 10.1016/S0006-3495(95)79956-8. Biophys J. 1995. PMID: 8519983 Free PMC article.

Cite

Share

9

Cite

Share

The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects.

Han TH, Blanchard RL, Palcza J, Martucci A, Miller-Stein CM, Gutierrez M, Panebianco D, Rippley RK, Lines C, Murphy MG. Han TH, et al. Among authors: rippley rk. Arch Drug Inf. 2010 Dec;3(4):55-62. doi: 10.1111/j.1753-5174.2010.00031.x. Arch Drug Inf. 2010. PMID: 21221171 Free PMC article.

Cite

Share

10

Cite

Share

A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects.

Decochez K, Rippley RK, Miller JL, De Smet M, Yan KX, Matthijs Z, Riffel KA, Song H, Zhu H, Maynor HO, Tanaka W, Johnson-Levonas AO, Davies MJ, Gottesdiener KM, Keymeulen B, Wagner JA. Decochez K, et al. Among authors: rippley rk. Drugs R D. 2006;7(2):99-110. doi: 10.2165/00126839-200607020-00004. Drugs R D. 2006. PMID: 16542056 Clinical Trial.

Cite

Share